Resident Training in Plaque Psoriasis
Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.
Topical vs Systemic Therapy in Plaque Psoriasis
Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.
Use of Topical Treatment in Plaque Psoriasis
Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.
The Pathogenesis of Plaque Psoriasis
Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.
Acne & Rosacea, Drug Actions, and Atopic Dermatitis Updates With James Del Rosso, DO
Del Rosso previews his upcoming sessions at SCALE 2023 discussing the latest updates in management and treatment techniques.
Differences in Isotretinoin Formulation
An expert in dermatology reviews the differences in Isotretinoin and highlights utilization requirements in patients prescribed this treatment.
Treatment Selection in Patients with Acne Vulgaris
Dr James Q Del Rosso discusses the benefit of combination therapy in the management of acne and highlights the importance of combating acne scarring.
Expert Perspective on the Management of Acne
James Q Del Rosso, DO, shares his insight into some causes of acne and the utility of clascoterone cream 1% combat this condition in both male and female patient populations.
TRuE-AD1 and TRuE-AD2 trials: Takeaway Points
James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.
Ruxolitinib: Clinical Context
Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.
TRuE-AD1 and TRuE AD2: Trial Data
James Q Del Rosso, DO, takes a closer look at the trial data regarding timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis.
Ruxolitinib Trial Results
James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.
TRuE-AD1 and TRuE AD2 Trial: Baseline Characteristics
Thought leaders provide an overview of the basline characteristics of the TRuE-AD1 and TRuE AD2 phase 3 trial.
TRuE-AD1 and TRuE AD2 Trial Overview
Dermatology experts review the design of the TRuE-AD1 and TRuE AD2 phase 3 trial.
Overview of Atopic Dermatitis
James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, provide an overview of atopic dermatitis and review the burden of disease.
JAK Inhibitors: Non-Responders and Safety Considerations
Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.
Oral JAK Inhibitors for Atopic Dermatitis
Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.
Topical JAK Inhibitors for Atopic Dermatitis
A review of topical JAK inhibitor ruxolitinib.
JAK Inhibitors: An Overview
James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.